BOSTON–(BUSINESS WIRE)–CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS). Award selection was announced at the SLAS2024 International Conference and Exhibition in Boston, MA on February 6th, 2024.

“We are honored to receive the peer-reviewed New Product Award from the Society for Laboratory Automation and Screening, a world-renowned organization dedicated to transforming life science research”

Post this

The SLAS New Product Awards Review Panel rigorously evaluates newcomers based on technical merit and commercial feasibility, along with other criteria such as market opportunity, impact of the product, originality, and proof of concept. Front-runners are interviewed on-site at the conference by a panel of industry veterans with deep expertise in laboratory automation and screening techniques to determine final award recipients.

Pixel dramatically accelerates the scale at which cell biology applications can be executed, and the breadth and depth of live-cell insights obtained. For the first time, scientists can now assess live cell function with simultaneous monitoring of cell viability, morphology, electrophysiology, metabolism, and more while generating non-invasive electrical ‘images’ with single-cell spatial resolution.

“We are honored to receive the peer-reviewed New Product Award from the Society for Laboratory Automation and Screening, a world-renowned organization dedicated to transforming life science research,” said Jeffrey Abbott, Ph.D., co-founder and CEO of CytoTronics. “We are energized by the level of interest in our first commercial offering, and are committed to pushing the boundaries of innovation this year as we gather critical insights that will fuel further development of Pixel for critical applications in cell biology.”

CytoTronics’ early-access program for Pixel empowers cell biologists to unlock applications that were previously inaccessible. Customers receive a Pixel Primo, a single plate reader that can be placed into any cell culture incubator, 96-well Pixel plates, and Pixel Pro, a cloud-based control and interactive analysis software. The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function. More applications supporting additional scale will be available later in 2024 with the release of Pixel Octo, a dedicated benchtop incubator with an integrated 8-plate reader.

SLAS2024 marked CytoTronics’ North American reveal of the Pixel system. The global debut continues next month with the Asia-Pacific reveal at INTERPHEX Week in Osaka Japan March 13-15, followed by the European reveal at ISSCR 2024 July 10-13 in Hamburg Germany, which will also showcase the company’s next product entry, the Pixel Octo system.

To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com or follow us on LinkedIn.

About Pixel
CytoTronics’ breakthrough semiconductor-to-live-cell interface enables thousands of multi-modal readouts on any cell type or organoid system. Live cell function is monitored on a Pixel plate, a proprietary 96- or 384-well microplate embedded with microchips at the base of each well. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well.

About CytoTronics
At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications. Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at www.cytotronics.com or follow us on LinkedIn.